Antibody Drug Conjugate News and Research

RSS
Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

iCAD introduces VersaVue Enterprise 3.2.1 MR software

iCAD introduces VersaVue Enterprise 3.2.1 MR software

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.